Activation of coagulation and fibrinolysis during cardiothoracic operations

被引:122
作者
Hunt, BJ [1 ]
Parratt, RN [1 ]
Segal, HC [1 ]
Sheikh, S [1 ]
Kallis, P [1 ]
Yacoub, M [1 ]
机构
[1] Harefield Hosp, Heart Sci Ctr, Natl Heart & Lung Inst, Imperial Coll Sch Med,Dept Cardiothorac Surg, Harefield UB9 6JH, Middx, England
关键词
D O I
10.1016/S0003-4975(97)01345-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. During open cardiac operations using cardiopulmonary bypass, there if activation of coagulation and fibrinolysis. We assessed the separate contributions of the surgical procedure itself and cardiopulmonary bypass to this, by studying sequential samples from patients undergoing routine open cardiac operations or thoracic operations without cardiopulmonary bypass. Methods. Activation of coagulation and the extent of fibrinolysis were measured from sequential samples obtained before the operation to 48 hours after the operation for 7 thoracic patients and 8 cardiac patients. Results. In the thoracic group operation length was shorter (p = 0.002), and there was no significant increase in thrombin-antitrombin III complexes or D-dimers until 24 hours postoperatively. In contrast, there was a highly significant increase in thrombin-antithrombin III complexes (p = 0.0043) and D-dimer levels (p = 0.009) during cardiopulmonary bypass. The increase in fibrinolytic activity was caused by an increase in tissue plasminogen activator (p = 0.013). At 48 hours postoperatively, the cardiac patients had a more hypercoagulable state than thoracic patients with significantly higher levels of thrombin-antithrombin III complexes (p = 0.041) and plasminogen activator inhibitor-1 activity (p = 0.0033). Conclusions. This study suggests the major activation of coagulation and fibrinolysis seen during cardiac operations is caused by the use of cardiopulmonary bypass. (C) 1998 by The Society of Thoracic Surgeons.
引用
收藏
页码:712 / 718
页数:7
相关论文
共 24 条
[1]  
ADELMAN B, 1985, BLOOD, V65, P32
[2]   COMPARISON OF THE EFFECTS OF APROTININ AND TRANEXAMIC ACID ON BLOOD-LOSS AND RELATED VARIABLES AFTER CARDIOPULMONARY BYPASS [J].
BLAUHUT, B ;
HARRINGER, W ;
BETTELHEIM, P ;
DORAN, JE ;
SPATH, P ;
LUNDSGAARDHANSEN, P .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1994, 108 (06) :1083-1091
[3]  
BOISCLAIR MD, 1993, BLOOD, V82, P3350
[4]  
BOISCLAIR MD, 1993, BLOOD COAGUL FIBRIN, V4, P1007, DOI 10.1097/00001721-199304060-00017
[5]   EVALUATION OF TESTS USED TO MONITOR HEPARIN THERAPY DURING EXTRACORPOREAL-CIRCULATION [J].
BULL, MH ;
HUSE, WM ;
BULL, BS .
ANESTHESIOLOGY, 1975, 43 (03) :346-353
[6]   ROLE OF FACTOR-XII IN THROMBIN GENERATION AND FIBRINOLYSIS DURING CARDIOPULMONARY BYPASS [J].
BURMAN, JF ;
CHUNG, HI ;
LANE, DA ;
PHILIPPOU, H ;
ADAMI, A ;
LINCOLN, JCR .
LANCET, 1994, 344 (8931) :1192-1193
[7]  
CHANDLER WL, 1995, THROMB HAEMOSTASIS, V74, P1293
[8]   Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass [J].
Chung, JH ;
Gikakis, N ;
Rao, AK ;
Drake, TA ;
Colman, RW ;
Edmunds, LH .
CIRCULATION, 1996, 93 (11) :2014-2018
[9]   APROTININ - A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC EFFICACY IN REDUCING BLOOD-LOSS ASSOCIATED WITH CARDIAC-SURGERY [J].
DAVIS, R ;
WHITTINGTON, R .
DRUGS, 1995, 49 (06) :954-983
[10]  
DEMEYER R, 1990, CURR OPIN ANESTHESIO, V3, P77